ATE214926T1 - Verwendung von (r-(z))-alpha-(methoxyimino)-alpha-(1-azabicycl (2.2.2.) oct-3-yl) acetonitril zur hemmung der amyloid-beta-a4-bildung bei der alzheimerschen krankheit - Google Patents
Verwendung von (r-(z))-alpha-(methoxyimino)-alpha-(1-azabicycl (2.2.2.) oct-3-yl) acetonitril zur hemmung der amyloid-beta-a4-bildung bei der alzheimerschen krankheitInfo
- Publication number
- ATE214926T1 ATE214926T1 AT95936515T AT95936515T ATE214926T1 AT E214926 T1 ATE214926 T1 AT E214926T1 AT 95936515 T AT95936515 T AT 95936515T AT 95936515 T AT95936515 T AT 95936515T AT E214926 T1 ATE214926 T1 AT E214926T1
- Authority
- AT
- Austria
- Prior art keywords
- alpha
- alzheimer
- disease
- pct
- acetonitrile
- Prior art date
Links
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 title abstract 5
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 4
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 1
- -1 acetonitrile compound Chemical class 0.000 abstract 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 1
- 230000007450 amyloidogenic pathway Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000020978 protein processing Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9421472A GB9421472D0 (en) | 1994-10-25 | 1994-10-25 | Novel methods |
| PCT/EP1995/004082 WO1996012486A1 (en) | 1994-10-25 | 1995-10-17 | Use of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta a4 formation in alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE214926T1 true ATE214926T1 (de) | 2002-04-15 |
Family
ID=10763350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95936515T ATE214926T1 (de) | 1994-10-25 | 1995-10-17 | Verwendung von (r-(z))-alpha-(methoxyimino)-alpha-(1-azabicycl (2.2.2.) oct-3-yl) acetonitril zur hemmung der amyloid-beta-a4-bildung bei der alzheimerschen krankheit |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5891887A (de) |
| EP (1) | EP0786998B1 (de) |
| JP (1) | JPH10509697A (de) |
| KR (1) | KR100393365B1 (de) |
| CN (1) | CN1085529C (de) |
| AT (1) | ATE214926T1 (de) |
| AU (1) | AU698695B2 (de) |
| BG (1) | BG101500A (de) |
| BR (1) | BR9509433A (de) |
| CZ (1) | CZ287370B6 (de) |
| DE (1) | DE69526102T2 (de) |
| DK (1) | DK0786998T3 (de) |
| ES (1) | ES2173977T3 (de) |
| GB (1) | GB9421472D0 (de) |
| HU (1) | HUT77007A (de) |
| NO (1) | NO312055B1 (de) |
| NZ (1) | NZ295155A (de) |
| PT (1) | PT786998E (de) |
| SK (1) | SK50497A3 (de) |
| WO (1) | WO1996012486A1 (de) |
| ZA (1) | ZA958946B (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU751607B2 (en) * | 1995-07-29 | 2002-08-22 | Smithkline Beecham Plc | Method of treatment of dementia |
| GB9619074D0 (en) * | 1996-09-12 | 1996-10-23 | Smithkline Beecham Plc | Composition |
| DE19641180A1 (de) * | 1996-09-24 | 1998-03-26 | Schering Ag | Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung |
| HUP0101043A3 (en) * | 1998-03-11 | 2002-02-28 | Smithkline Beecham Corp | Controlled release oral dosage form containing [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl]acetonitrile monohydrochlorid and process for its preparation |
| GB9815383D0 (en) * | 1998-07-15 | 1998-09-16 | Smithkline Beecham Plc | Novel method of treatment |
| US6245884B1 (en) * | 1998-10-16 | 2001-06-12 | Vivian Y. H. Hook | Secretases related to alzheimer's dementia |
| US7816149B2 (en) * | 2004-03-29 | 2010-10-19 | Applied Photonics Worldwide, Inc. | Nanobioprocessor for protein and cell therapy |
| GB0428170D0 (en) * | 2004-12-23 | 2005-01-26 | Biopartners Ltd | Mono and Combination Therapy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG48315A1 (en) * | 1989-04-13 | 1998-04-17 | Beecham Group Plc | Novel compounds |
| US5385915A (en) * | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
| JPH0725786A (ja) * | 1990-05-16 | 1995-01-27 | Univ Rockefeller | アルツハイマー病を伴うアミロイドーシスの治療 |
| US5242932A (en) * | 1991-12-17 | 1993-09-07 | The Rockefeller University | Treatment of amyloidosis associated with alzheimer disease |
| MX9300875A (es) * | 1992-02-20 | 1993-08-31 | Smithkline Beecham Plc | Procedimiento para la preparacion de compuestos azabiciclicos. |
| WO1994009370A1 (en) * | 1992-10-09 | 1994-04-28 | Massachusetts Institute Of Technology | Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors |
| GB9409705D0 (en) * | 1994-05-14 | 1994-07-06 | Smithkline Beecham Plc | Novel compounds |
-
1994
- 1994-10-25 GB GB9421472A patent/GB9421472D0/en active Pending
-
1995
- 1995-10-17 US US08/836,013 patent/US5891887A/en not_active Expired - Fee Related
- 1995-10-17 AU AU38431/95A patent/AU698695B2/en not_active Ceased
- 1995-10-17 NZ NZ295155A patent/NZ295155A/en unknown
- 1995-10-17 PT PT95936515T patent/PT786998E/pt unknown
- 1995-10-17 CN CN95196837A patent/CN1085529C/zh not_active Expired - Fee Related
- 1995-10-17 SK SK504-97A patent/SK50497A3/sk unknown
- 1995-10-17 DK DK95936515T patent/DK0786998T3/da active
- 1995-10-17 DE DE69526102T patent/DE69526102T2/de not_active Expired - Fee Related
- 1995-10-17 EP EP95936515A patent/EP0786998B1/de not_active Expired - Lifetime
- 1995-10-17 ES ES95936515T patent/ES2173977T3/es not_active Expired - Lifetime
- 1995-10-17 HU HU9701815A patent/HUT77007A/hu unknown
- 1995-10-17 WO PCT/EP1995/004082 patent/WO1996012486A1/en not_active Ceased
- 1995-10-17 AT AT95936515T patent/ATE214926T1/de not_active IP Right Cessation
- 1995-10-17 CZ CZ19971251A patent/CZ287370B6/cs not_active IP Right Cessation
- 1995-10-17 KR KR1019970702700A patent/KR100393365B1/ko not_active Expired - Fee Related
- 1995-10-17 JP JP8513628A patent/JPH10509697A/ja not_active Ceased
- 1995-10-17 BR BR9509433A patent/BR9509433A/pt not_active Application Discontinuation
- 1995-10-23 ZA ZA958946A patent/ZA958946B/xx unknown
-
1997
- 1997-04-24 NO NO19971899A patent/NO312055B1/no not_active IP Right Cessation
- 1997-05-20 BG BG101500A patent/BG101500A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK50497A3 (en) | 1997-09-10 |
| US5891887A (en) | 1999-04-06 |
| NO312055B1 (no) | 2002-03-11 |
| GB9421472D0 (en) | 1994-12-07 |
| KR100393365B1 (ko) | 2003-12-18 |
| NO971899L (no) | 1997-04-24 |
| KR970706816A (ko) | 1997-12-01 |
| CN1170365A (zh) | 1998-01-14 |
| MX9703077A (es) | 1997-07-31 |
| BG101500A (en) | 1998-01-30 |
| PT786998E (pt) | 2002-09-30 |
| EP0786998B1 (de) | 2002-03-27 |
| CZ125197A3 (en) | 1997-07-16 |
| AU3843195A (en) | 1996-05-15 |
| EP0786998A1 (de) | 1997-08-06 |
| CZ287370B6 (en) | 2000-11-15 |
| CN1085529C (zh) | 2002-05-29 |
| HUT77007A (hu) | 1998-03-02 |
| DE69526102D1 (de) | 2002-05-02 |
| NO971899D0 (no) | 1997-04-24 |
| NZ295155A (en) | 2000-07-28 |
| JPH10509697A (ja) | 1998-09-22 |
| WO1996012486A1 (en) | 1996-05-02 |
| AU698695B2 (en) | 1998-11-05 |
| ZA958946B (en) | 1996-08-20 |
| HK1002057A1 (en) | 1998-07-31 |
| ES2173977T3 (es) | 2002-11-01 |
| BR9509433A (pt) | 1997-09-16 |
| DE69526102T2 (de) | 2002-10-31 |
| DK0786998T3 (da) | 2002-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU71901A (sh) | NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA | |
| ATE204178T1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
| DE69400799D1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| BRPI0108977B8 (pt) | compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo | |
| KR900015730A (ko) | 정신장해 치료방해 | |
| ATE185268T1 (de) | Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin | |
| DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
| MXPA03010843A (es) | Uso de derivados con azetidinona en el tratamiento de enfermedad de alzheimer. | |
| BR0211119A (pt) | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto | |
| PT840601E (pt) | Thip para o tratamento de desordens do sono | |
| HUT77627A (hu) | 2,2-Diklór-alkánkarbonsavak, eljárás előállításukra és ezeket tartalmazó, inzulinrezisztencia kezelésére alkalmazható gyógyszerkészítmények | |
| DE4394931T1 (de) | Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen | |
| GEP20053423B (en) | Method of Inhibiting Amyloid Protein Aggregation and Method for Imaging of Amyloid Deposits | |
| ATE214926T1 (de) | Verwendung von (r-(z))-alpha-(methoxyimino)-alpha-(1-azabicycl (2.2.2.) oct-3-yl) acetonitril zur hemmung der amyloid-beta-a4-bildung bei der alzheimerschen krankheit | |
| HUP0202525A2 (hu) | Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit | |
| BR0212249A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto | |
| SE8903529D0 (sv) | Medical use | |
| TR200103561T2 (tr) | Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları | |
| BR0211358A (pt) | Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis | |
| ATE147978T1 (de) | Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit | |
| DE69421705D1 (de) | Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen | |
| BR9913242A (pt) | Uso de r(+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-p iperidinametanol para o tratamento de desordens de sono | |
| Bizzett | The Aetiology, Bacteriology, Pathology, Treatment of Pyorrhea Alveolaris | |
| ATE339199T1 (de) | Methoden zur kolikenbehandlung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0786998 Country of ref document: EP |
|
| EEIH | Change in the person of patent owner | ||
| REN | Ceased due to non-payment of the annual fee |